Nutra Pharma to Present at Upcoming Investment Conference

CORAL SPRINGS, FL--(Marketwired - Sep 9, 2015) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, will be presenting at the upcoming See Thru Equities Conference being held at the Convene Grand Central in New York City on Thursday, September 10th. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers, Nyloxin® and Pet Pain-Away, as well as discussing the Company's drug product pipeline. This will include a presentation on the designation of Orphan Drug Status for RPI-78M in the treatment of juvenile Multiple Sclerosis (MS).

"This conference provides an excellent opportunity to expand our presence within the investment community and share our unique and exciting growth story," commented Rik J Deitsch, CEO of Nutra Pharma. "We have been moving our therapeutics platform forward while we are still increasing the global distribution of our OTC products, Nyloxin and Pet Pain-Away," he continued. "See Thru Equities initiated coverage on us a few months ago, presenting some compelling data on the continuing successes of Nutra Pharma. I want to take this opportunity to expand on that report and share our exciting story with the investing public," he concluded.

SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street. Mr. Deitsch will be presenting at 9:30am ET in the Pershing Hub room.

For more information on the Conference, see: http://steconference.com

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The presentation at the See Thru Equities Conference should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.